Literature DB >> 10528159

Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans.

G B Huffnagle1, L K McNeil, R A McDonald, J W Murphy, G B Toews, N Maeda, W A Kuziel.   

Abstract

After intratracheal inoculation of the AIDS-associated pathogen Cryptococcus neoformans, 12-wk survival was >90% for CCR5+/+ mice but <25% for CCR5-/- mice. There were no defects in lung leukocyte recruitment (wk 5), pulmonary clearance, or delayed-type hypersensitivity in CCR5-/- mice. However, CCR5-/- mice had defects in leukocyte recruitment into the brain and, strikingly, in elimination of cryptococcal polysaccharide from the brain. In nonimmune CCR5-/- mice, there was a significant defect in macrophage recruitment after challenge with shed cryptococcal products (C. neoformans filtrate Ag) but not other nonspecific stimuli. Thus, CCR5 plays specific roles in innate immunity and organ-specific leukocyte trafficking during host defense against C. neoformans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528159

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Authors:  T Dragic; A Trkola; D A Thompson; E G Cormier; F A Kajumo; E Maxwell; S W Lin; W Ying; S O Smith; T P Sakmar; J P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

Review 2.  Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury.

Authors:  Ricky Maung; Kathryn E Medders; Natalia E Sejbuk; Maya K Desai; Rossella Russo; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-29       Impact factor: 4.147

3.  CCR5 dictates the equilibrium of proinflammatory IL-17+ and regulatory Foxp3+ T cells in fungal infection.

Authors:  Danielle N Kroetz; George S Deepe
Journal:  J Immunol       Date:  2010-03-24       Impact factor: 5.422

Review 4.  Chemokine control of lymphocyte trafficking: a general overview.

Authors:  Jens V Stein; César Nombela-Arrieta
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

5.  The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density.

Authors:  Caroline Desmetz; Yea-Lih Lin; Clément Mettling; Pierre Portalès; Herisoa Rabesandratana; Jacques Clot; Pierre Corbeau
Journal:  Immunology       Date:  2006-12       Impact factor: 7.397

6.  The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi.

Authors:  Jenny L Hardison; Ruth A Wrightsman; Philip M Carpenter; William A Kuziel; Thomas E Lane; Jerry E Manning
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 7.  Immune response and immunotherapy to Cryptococcus infections.

Authors:  Qing Zhou; William J Murphy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

8.  Double-edged genetic swords and immunity: lesson from CCR5 and beyond.

Authors:  Sunil K Ahuja; Weijing He
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

9.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

10.  CCR2 mediates conventional dendritic cell recruitment and the formation of bronchovascular mononuclear cell infiltrates in the lungs of mice infected with Cryptococcus neoformans.

Authors:  John J Osterholzer; Jeffrey L Curtis; Timothy Polak; Theresa Ames; Gwo-Hsiao Chen; Rod McDonald; Gary B Huffnagle; Galen B Toews
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.